股票代码：******

Jiangxi Bio Deeply Cultivates the Hai Zhi Brand, Jointly Exploring Cutting-Edge Technologies

Published:

2026-06-29

To further advance Jiangxi Province’s “Ganhai Huizhi” international science and technology exchange and cooperation initiative, attract cutting-edge global expertise, overcome technical barriers in the biopharmaceutical sector, and boost the quality and efficiency of the antiserum industry, Jiangxi Biological Products Research Institute Co., Ltd. hosted the “Ganhai Huizhi” Bangladesh Expert Antiserum Technology Exchange Conference in Ji’an City from June 13 to 14, 2026. The event was co-organized by the Jiangxi Provincial Association for Science and Technology and the Ji’an Municipal Association for Science and Technology. Senior Bangladeshi experts in the biopharmaceutical field, Saleh Mohammad Zillur Rahman and Abdul Wahab Khan, were invited to attend, joining key personnel from the company’s R&D, manufacturing, quality control, and international business teams. Together, they engaged in in-depth discussions on前沿 antiserum technologies, product iteration and upgrades, joint research and development, and international market collaboration, successfully establishing an international platform for technological exchange, resource sharing, and mutually beneficial cooperation between China and Bangladesh.

As a leading domestic biopharmaceutical company with over fifty years of expertise in the antiserum field, Jiangxi Bio has consistently placed technological innovation at the heart of its development. Relying on a growth model that integrates “technology + a full industrial chain + pilot-scale platform for translation,” the company is strategically focusing on cutting-edge areas such as next-generation antibody research and development, while vigorously tackling critical technological bottlenecks that constrain the industry. This exchange event not only represents an important step for the company to leverage high‑level international expertise and overcome innovation barriers, but also serves as a vivid demonstration of the successful implementation and tangible results of our province’s “Ganhai Hui Zhi” initiative.

During the event, both sides engaged in comprehensive, multi‑level technical exchanges. In the technical discussion session, domestic and international teams thoroughly evaluated the existing product quality system, conducted in‑depth deliberations on pathways for quality improvement, and identified key technical gaps and areas for optimization. In the new‑product review session, the two parties meticulously analyzed the technical roadmaps and R&D challenges for pipeline products such as antiserums and equine immunoglobulins, while aligning with international industry standards to clarify the requirements for overseas regulatory registration, thereby articulating a clear development strategy for bringing these new products to the global market.

In addition to exchanges, the foreign experts visited the R&D laboratory, the pilot‑scale platform, and the production workshop, conducting on‑site inspections of manufacturing processes, experimental workflows, and quality‑control systems. They addressed questions on the spot, engaged in hands‑on discussions, and, drawing on their industry expertise, put forward a number of specialized recommendations for improvement. During the collaborative negotiations, both sides held thorough consultations on joint R&D, technology licensing, international market access, and overseas registration applications, reaching several agreements in principle and laying a solid foundation for establishing a long‑term, regular cross‑border technical cooperation mechanism.

This exchange event yielded substantial results: it not only produced a comprehensive technical improvement report on antitoxin products and finalized several cooperation agreements, but also significantly enhanced the enterprise team’s expertise in antibody drug R&D, pilot-scale process optimization, and international regulatory compliance. Leveraging the “Ganhai Huizhi” platform, the company has further broadened its global outlook, deepened cross‑border technological collaboration, and continuously strengthened its core competitiveness.

Going forward, the Jiangxi Association for Science and Technology will continue to leverage provincial and municipal platforms for international exchange, attract top talent and expertise, deepen international scientific and technological cooperation, and accelerate breakthroughs in cutting-edge technologies and the commercialization of innovative成果. By fully harnessing the exemplary role of leading enterprises, it will continually expand the portfolio of “Ganhai Hui Zhi” best‑practice cases, thereby supporting the high‑quality development of Jiangxi Province’s “Future Biotechnology” sector and steadily enhancing the international influence and overall competitiveness of the region’s biopharmaceutical industry.

Jiangxi Sets Sail, HongKong Rings the Bell: The Celebration of JIANGXI BIO’s Listing on the Main Board of the Hong Kong Stock Exchange Concludes Successfully

Jiangxi Bio Aligns with Digital Intelligence Benchmarks, Focusing on Quality Improvement and Efficiency Gains

Add:

Address: No. 198 Huoju Avenue, Jinggangshan Economic & Technological Development Zone, Ji’an, Jiangxi, China

Board Office:

Domestic Sales:

International Sales: